Creative Planning
HUMA icon

Creative Planning’s Humacyte HUMA Stock Holding History

Creative Planning’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.9K Buy
111,342
+6,223
+6% +$5.77K ﹤0.01% 4062
2026
Q1 		$63.8K Buy
105,119
+49,204
+88% +$51.2K ﹤0.01% 3964
2025
Q4 		$53.7K Buy
55,915
+11,903
+27% +$16.9K ﹤0.01% 3797
2025
Q3 		$76.6K Buy
+44,012
New +$86.2K ﹤0.01% 3708

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Creative Planning's HUMA Position: Q2 2026 in Review

Creative Planning increased its Humacyte (HUMA) stake by 5.9% in Q2 2026, buying an estimated $5.77K and bringing the position to 111,342 shares worth $86.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4062.

Creative Planning first reported a position in HUMA in Q3 2025 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Creative Planning held 111,342 shares of Humacyte worth $86.9K as of Q2 2026.
  • Creative Planning bought 6,223 Humacyte shares in Q2 2026, an estimated $5.77K.
  • Humacyte made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #4062 holding.
  • Creative Planning first reported a position in Humacyte in Q3 2025 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.